Better patient compliance with Copaxone ollow-up analysis of an ongoing study of multiple sclerosis patients has found that after six years more than half of the patients taking Copaxone had remained on treatment continuously, Teva Neuroscience has said. The study compared these results to patients taking an alternative treatment for MS called interferon beta. Only 30% of patients taking interferon beta remained on the treatment.

The study included patients receiving Copaxone or interferon beta treatments including Avonex, Betaseron or Rebif. All are known as immunomodulatory therapies (IMTs)..